Baxter Pharmaceuticals India Private Limited

Baxter Pharmaceuticals India Private Limited (BPIPL) is a private unlisted company incorporated on June 8, 2005, under the Corporate Identification Number (CIN) U24230GJ2005PTC046211. The company is registered with the Ministry of Corporate Affairs (MCA) in India. BPIPL operates in the pharmaceutical manufacturing sector, focusing on the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company's authorized capital is ₹2,000 crore, with a paid-up capital of ₹5.73 lakh.

BPIPL's registered office is located at Village: Vasana-Chacharwadi Tal: Sanand, Vasana Chacharwadi, Gujarat 382213, India. The company is a wholly owned subsidiary of Baxter International Inc., a global healthcare company. Baxter India has been serving its mission to save and sustain lives for over 25 years, with a robust presence across India, including manufacturing facilities in Ahmedabad and research and development centers in Bengaluru and Ahmedabad.

BPIPL operates a state-of-the-art manufacturing facility in Ahmedabad, Gujarat, which formulates, fills, and finishes a broad portfolio of essential generic medicines. The facility specializes in anesthesia and analgesics, critical care, renal medicines, and anti-infectives, offering products in various presentations such as bags, vials, and ampoules. The plant has been operational since 2016 and has been producing nearly 90 million units annually, exporting products to over 60 countries.

As of March 2026, BPIPL's board of directors includes:

• Sanju Dhawan
• Anuranjan Naresh
• Tripti Sapra
• Ashwin Prakash Upasane
• Anurag Bharatkumar Pachchigar
• Gurjeet Singh Bedi

The company has experienced changes in its leadership over the years, with new directors appointed in 2021 and 2024. Specific details regarding the CEO, CFO, and other key executives are not publicly disclosed.

BPIPL's manufacturing facility in Ahmedabad has been inspected and approved by several international regulatory authorities:

• United Kingdom: The Medicines and Healthcare products Regulatory Agency (MHRA) issued a Good Manufacturing Practice (GMP) certificate (UK GMP 44139) following an inspection on February 5, 2024. (cms.mhra.gov.uk)

• United States: The U.S. Food and Drug Administration (FDA) has conducted inspections of BPIPL's facility. The most recent inspection, as of March 2026, resulted in an "official action indicated" classification, indicating that while issues were found, the facility was permitted to correct them voluntarily.

• European Union: BPIPL's facility has been inspected and approved by the European Medicines Agency (EMA), ensuring compliance with EU GMP standards.

• Australia: The Therapeutic Goods Administration (TGA) has recognized BPIPL's facility, allowing the company to export pharmaceutical products to Australia.

• Japan: BPIPL has obtained the necessary approvals from the Pharmaceuticals and Medical Devices Agency (PMDA) to market its products in Japan.

These approvals demonstrate BPIPL's commitment to maintaining high manufacturing standards and its ability to meet the stringent requirements of major regulated markets.

BPIPL has expanded its presence in emerging markets, including Africa, Latin America, and Southeast Asia. The company's manufacturing facility in Ahmedabad has been inspected and approved by the World Health Organization (WHO), enabling BPIPL to supply essential medicines to these regions. This WHO prequalification facilitates access to a broader range of markets, enhancing BPIPL's global footprint.

BPIPL's export data indicates a strong focus on the gastrointestinal and diuretics therapeutic categories, with 59.9% and 36.2% market share, respectively. The company's portfolio is highly concentrated, with the top five products accounting for 100% of its exports. This concentration suggests a strategic emphasis on specific therapeutic areas, potentially reducing diversification and increasing exposure to market fluctuations in these segments.

BPIPL's manufacturing facility in Ahmedabad is registered with the U.S. FDA, allowing the company to export pharmaceutical products to the United States. The facility has undergone multiple FDA inspections, with the most recent resulting in an "official action indicated" classification. This indicates that while issues were identified, the facility was permitted to correct them voluntarily. The FDA has not issued any warning letters or import alerts against BPIPL's facility.

BPIPL's manufacturing facility in Ahmedabad has been inspected and approved by the World Health Organization (WHO), ensuring compliance with international standards for the production of pharmaceutical products. Additionally, the facility holds a Good Manufacturing Practice (GMP) certificate from the European Medicines Agency (EMA), confirming adherence to EU GMP standards.

BPIPL's manufacturing facility in Ahmedabad holds the necessary licenses from the Central Drugs Standard Control Organisation (CDSCO), the national regulatory authority in India. The facility has been inspected and approved by the CDSCO, ensuring compliance with Indian pharmaceutical manufacturing standards. BPIPL has also obtained the required export No Objection Certificates (NOCs) from the Directorate General of Foreign Trade (DGFT), facilitating its export operations.

As of March 2026, BPIPL's manufacturing facility in Ahmedabad has undergone multiple inspections by the U.S. FDA, with the most recent resulting in an "official action indicated" classification. This classification indicates that while issues were identified, the facility was permitted to correct them voluntarily. The FDA has not issued any warning letters or import alerts against BPIPL's facility.

BPIPL operates in a competitive landscape, focusing on the production of generic injectables in therapeutic areas such as anesthesia, analgesics, critical care, renal medicines, and anti-infectives. The company's top competitors in these categories include:

• Sun Pharmaceutical Industries Ltd.: A leading Indian pharmaceutical company with a diverse portfolio, including generic injectables.

• Cipla Ltd.: A global pharmaceutical company offering a wide range of generic medicines, including injectables.

• Dr. Reddy's Laboratories Ltd.: An Indian multinational pharmaceutical company with a significant presence in the generic injectables market.

BPIPL's market share in its top five products is as follows:

• Furosemide: 10.1% market share

• Ondansetron: 8.9% market share

• Metoclopramide: 4.2% market share

• Tobramycin: 1.5% market share

• Imipenem: 0.5% market share

This distribution indicates that BPIPL holds a leading position in the furosemide segment, while other products have relatively smaller market shares.

BPIPL's key differentiators include:

• Manufacturing Excellence: The Ahmedabad facility is equipped with state-of-the-art infrastructure, adhering to stringent quality controls and international GMP standards.

• Regulatory Approvals: The facility holds approvals from major regulatory bodies, including the FDA, EMA, MHRA, and WHO, facilitating access to global markets.

• Product Portfolio: BPIPL offers a broad range of essential generic medicines, with a strong presence in anesthesia, analgesics, critical care, renal medicines, and anti-infectives.

BPIPL's current strategic direction focuses on the production of generic injectables in specific therapeutic areas, leveraging its manufacturing capabilities and regulatory approvals to serve both domestic and international markets. The company's future outlook includes expanding its product portfolio, enhancing